PMCB has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
PMCB has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, PharmaCyte Biotech's enterprise value is $-25.43 Mil. PharmaCyte Biotech's EBITDA for the trailing twelve months (TTM) ended in Jan. 2024 was $-4.12 Mil. Therefore, PharmaCyte Biotech's EV-to-EBITDA for today is 6.18.
The historical rank and industry rank for PharmaCyte Biotech's EV-to-EBITDA or its related term are showing as below:
During the past 13 years, the highest EV-to-EBITDA of PharmaCyte Biotech was 6.18. The lowest was -50.93. And the median was -4.38.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-05-03), PharmaCyte Biotech's stock price is $2.16. PharmaCyte Biotech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jan. 2024 was $-1.200. Therefore, PharmaCyte Biotech's PE Ratio for today is At Loss.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
The historical data trend for PharmaCyte Biotech's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PharmaCyte Biotech Annual Data | |||||||||||||||||||||
Trend | Apr14 | Apr15 | Apr16 | Apr17 | Apr18 | Apr19 | Apr20 | Apr21 | Apr22 | Apr23 | |||||||||||
EV-to-EBITDA | Get a 7-Day Free Trial | -11.83 | -10.28 | -11.29 | 8.76 | 4.40 |
PharmaCyte Biotech Quarterly Data | ||||||||||||||||||||
Apr19 | Jul19 | Oct19 | Jan20 | Apr20 | Jul20 | Oct20 | Jan21 | Apr21 | Jul21 | Oct21 | Jan22 | Apr22 | Jul22 | Oct22 | Jan23 | Apr23 | Jul23 | Oct23 | Jan24 | |
EV-to-EBITDA | Get a 7-Day Free Trial | 2.87 | 4.40 | 7.34 | 8.86 | 6.08 |
For the Biotechnology subindustry, PharmaCyte Biotech's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, PharmaCyte Biotech's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where PharmaCyte Biotech's EV-to-EBITDA falls into.
PharmaCyte Biotech's EV-to-EBITDA for today is calculated as:
EV-to-EBITDA | = | Enterprise Value (Today) | / | EBITDA (TTM) |
= | -25.432 | / | -4.118 | |
= | 6.18 |
PharmaCyte Biotech's current Enterprise Value is $-25.43 Mil.
PharmaCyte Biotech's EBITDA for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.12 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PharmaCyte Biotech (NAS:PMCB) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
PharmaCyte Biotech's PE Ratio for today is calculated as:
PE Ratio | = | Share Price (Today) | / | Earnings per Share (Diluted) (TTM) |
= | 2.16 | / | -1.200 | |
= | At Loss |
PharmaCyte Biotech's share price for today is $2.16.
PharmaCyte Biotech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.200.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Please read Which price ratio outperforms the enterprise multiple?
Thank you for viewing the detailed overview of PharmaCyte Biotech's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Wayne Remell Walker | director | 1515 MARKET STREET, SUITE 1720, PHILADELPHIA PA 19103 |
Robert Weinstein | director | 3960 HOWARD HUGHES PARKWAY, SUITE 500, LAS VEGAS NV 89169 |
Jack E Stover | director | C/O SICOR INC, 19 HUGHES, IRVINE CA 92618-1902 |
Daniel Stuart Farb | director | 100 ESSEX RD., CHESTNUT HILL MA 02467 |
Jonathan Schechter | director | C/O ATRINSIC, INC. 1 GRAND CENTRAL PLACE, SUITE 2319, NEW YORK NY 10165 |
Daniel Allen | director | 299 PARK AVENUE SOUTH, SUITE 90959, NEW YORK NY 10003 |
Joshua Silverman | director | IROQUOIS CAPITAL MANAGEMENT LLC, 205 EAST 42ND ST - 20TH FL., NEW YORK NY 10017 |
Matthias Loehr | director | 3960 HOWARD HUGHES PARKWAY, SUITE 500, LAS VEGAS NV 89169 |
Yuen Thomas C K | director | |
Carlos Trujillo | director, officer: CFO | 8105 IRVINE CENTER DR. #820, IRVINE CA 92618 |
Kenneth L. Waggoner | director, officer: Chairman, CEO, Pres and GC | 8105 IRVINE CENTER DR. #820, IRVINE CA 92618 |
Gerald W Crabtree | director, officer: Chief Science Officer | 12510 PROSPERITY DR., SUITE #310, SILVER SPRING MD 20904 |
Thomas Liquard | director | C/O PHARMACYTE BIOTECH INC., 23046 AVENIDA DE LE CORLOTA, LAGUNA HILLS CA 92653 |
Raymond Cf Tong | director | C/O PHARMACYTE BIOTECH INC., 23046 AVENIDA DE LE CORLOTA, LAGUNA HILLS CA 10041-0099 |
Michael M Abecassis | director | C/O PHARMACYTE BIOTECH INC., 23046 AVENIDA DE LE CORLOTA, LAGUNA HILLS CA 10041-0099 |
From GuruFocus
By PRNewswire PRNewswire • 07-13-2022
By Business Wire Business Wire • 06-13-2022
By PRNewswire PRNewswire • 07-09-2022
By Business Wire • 10-31-2023
By PRNewswire PRNewswire • 06-30-2022
By Business Wire • 10-31-2023
By Business Wire Business Wire • 07-11-2022
By PRNewswire PRNewswire • 07-15-2022
By Business Wire Business Wire • 07-28-2022
By Business Wire Business Wire • 07-19-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.